Welcome to our dedicated page for 2Seventy Bio news (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2Seventy Bio stock.
2seventy bio, Inc. (Nasdaq: TSVT) is an immuno-oncology cell therapy company centered on Abecma (idecabtagene vicleucel; ide-cel), a BCMA-directed autologous CAR T cell therapy for adult patients with relapsed or refractory multiple myeloma after at least two prior lines of therapy. The TSVT news stream features company announcements that combine scientific, commercial, and corporate developments related to this program and its broader collaboration with Bristol Myers Squibb (BMS).
Investors and observers following TSVT news will find regular updates on Abecma’s U.S. commercial performance, including quarterly and full-year revenues as reported by BMS, trends in demand such as patients undergoing apheresis, and commentary on Abecma’s role in the multiple myeloma treatment landscape. Releases also discuss regulatory milestones, label expansions into earlier-line settings, and decisions around clinical studies such as the discontinuation of enrollment in the Phase 3 KarMMa-9 trial in newly diagnosed multiple myeloma.
Corporate and financial news for 2seventy bio includes quarterly earnings reports, changes in operating expenses, net cash spend, and cash, cash equivalents, and marketable securities. The company has reported transactions such as the sale of its oncology R&D business to Regeneron and the sale of its Hemophilia A program and gene editing technology to Novo Nordisk, which it characterizes as supporting an exclusive focus on Abecma. Conference participation and investor events, including healthcare conferences and fireside chats, are also covered in TSVT news items.
A key current theme in 2seventy bio’s news is its definitive merger agreement with Bristol Myers Squibb. News releases describe the agreed all-cash acquisition, the tender offer structure, the Hart-Scott-Rodino review process, and the expectation that, following completion of the transaction and a second-step merger, 2seventy bio’s common stock will no longer trade on Nasdaq. For readers tracking TSVT, the news page provides an evolving record of Abecma’s commercial trajectory, strategic partnerships, and the company’s pending transition into BMS.
2seventy bio, Inc. (NASDAQ: TSVT) has announced the immediate appointment of Dr. Wei Lin to its Board of Directors. Dr. Lin brings extensive experience in clinical development, particularly in cancer immunotherapy, which is essential for the company during its growth phase. His previous roles include Chief Medical Officer at Erasca and Head of Development at Nektar Therapeutics. Dr. Lin’s expertise is expected to enhance 2seventy's strategies in developing novel treatments, aligning with the company's mission to innovate therapies for cancer patients.
2seventy bio, Inc. (NASDAQ: TSVT) will present at the 43rd Annual TD Cowen Health Care Conference on March 7, 2023, at 10:30 AM ET in Boston, MA. The management team will discuss the company's innovative approaches to immuno-oncology and cellular therapies aimed at treating various cancer types. A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days afterward. 2seventy bio is focused on developing groundbreaking therapies to disrupt the cancer treatment landscape through rapid and genuine innovation.
Marengo Therapeutics, Inc. announced the appointment of Kevin Chin, M.D., M.S., as the new Chief Medical Officer on March 1, 2023. Dr. Chin brings extensive experience in oncology clinical development, particularly in T cell-directed immunotherapies. He will oversee the company's clinical portfolio, including the START-001 Phase 1/2 clinical trial for STAR0602, an innovative immunotherapy targeting T cell receptors to enhance cancer treatment. Marengo's CEO, Zhen Su, emphasized the significance of Dr. Chin’s expertise as the company advances its promising pipeline and capitalizes on the STAR platform's development opportunities.
2seventy bio (NASDAQ: TSVT) announced the pricing of a public offering of 10,869,566 shares at $11.50 per share, aimed to raise approximately
2seventy bio, Inc. (NASDAQ: TSVT) has announced an underwritten public offering of $100 million in common stock, with a potential additional $15 million from underwriters. The offering is contingent on market conditions and is managed by Goldman Sachs, Cowen, and SVB Securities. This move is part of the company's ongoing efforts in cell and gene therapy for cancer treatments. The shares are being offered under a registration statement with the SEC that is effective since November 2022. The company aims to utilize the proceeds to further their mission in developing innovative cancer therapies.
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive results from the pivotal Phase 3 KarMMa-3 study of Abecma (idecabtagene vicleucel) for patients with relapsed and refractory multiple myeloma. Abecma showed a significant improvement in median progression-free survival (PFS) of 13.3 months versus 4.4 months for standard regimens. The study demonstrated a 51% reduction in risk of disease progression or death. Overall response rates were also significantly higher for Abecma at 71%, with 39% achieving a complete response. Safety results were consistent with prior data, with no new safety signals reported.
2seventy bio, Inc. (Nasdaq: TSVT) announced participation in two upcoming investor conferences. The first event is the Guggenheim Oncology Conference on February 9 at 9:00 am ET, held at the St. Regis New York. The second is the SVB Securities Global Biopharma Conference on February 15 at 10:00 am ET, conducted virtually. Both events will feature a fireside chat with management. Investors can access a live webcast and find a replay on the company's website, which will be available for 30 days post-event. 2seventy bio focuses on developing innovative immuno-oncology cell therapies to disrupt cancer treatment.
2seventy bio, Inc. (Nasdaq: TSVT) projects 2023 U.S. revenue for Abecma (idecabtagene vicleucel) between $470-$570M, driven by increased manufacturing capacity and positive clinical data from the KarMMa-3 study. The company aims to submit a supplemental Biologics Licensing Application in Q1 2023. Strong cash position of approximately $288M supports operations into 2025, with a focus on expanding the Abecma label and advancing other clinical studies. Noteworthy collaborations include a $20M investment from Regeneron to enhance cell therapy development.
Deep Genomics has enhanced its Board of Directors and Scientific Advisory Board with notable industry leaders to strengthen its AI-driven drug development capabilities. The new board members include Jacqueline Fok from SoftBank, Nessan Bermingham of Khosla Ventures, and William Baird, CFO of 2Seventy Bio. Experts in oligonucleotides, Arthur Krieg and Mark Edbrooke, also join the Scientific Advisory Board. This strategic move aims to advance the company's mission of utilizing AI to create innovative RNA-targeted therapeutics for genetically driven diseases.
2seventy bio announced an expanded collaboration with Regeneron to enhance cell therapy development for solid tumors. Regeneron is investing $20 million in equity and covering 100% of clinical development costs for specific trials. This partnership aims to accelerate the identification of innovative therapies through a combination of 2seventy's cell therapy platform and Regeneron's antibodies. The collaboration reflects mutual commitment to advance CAR-T and TCR programs and utilize a multi-arm approach for clinical studies.
FAQ
What is the current stock price of 2Seventy Bio (TSVT)?
What is the market cap of 2Seventy Bio (TSVT)?
